Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Europe“
Suchtreffer
Begriffe & Kennungen
Olanzapine Glenmark Europe · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with know
Eintrag öffnenOlanzapine Glenmark Europe · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with know
Eintrag öffnenOlanzapine Glenmark Europe · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenOlanzapine Glenmark Europe · 4.4 Special warnings and precautions for use · 2
Eintrag öffnenOlanzapine Glenmark Europe · 4.4 Special warnings and precautions for use · 3
Eintrag öffnenOlanzapine Glenmark Europe · 4.4 Special warnings and precautions for use · 4
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 Interaction with other medicinal products and other forms of interaction · 2
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 Interaction with other medicinal products and other forms of interaction · 3
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 Interaction with other medicinal products and other forms of interaction · 4
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · 21 Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is requ
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · 36 Olanzapine showed no interaction when co-administered with lithium or biperiden.
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · 51 Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is requ
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · 6 Olanzapine showed no interaction when co-administered with lithium or biperiden.
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · Decreased bioavailability Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · Decreased bioavailability Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · Decreased bioavailability Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · Decreased bioavailability Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been fo
Eintrag öffnenOlanzapine Glenmark Europe · 4.5 · Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been fo
Eintrag öffnen